ARRY-382 / CSF1R

Target: CSF1R | Disease State: Cancer

Program Description

ARRY-382 is a wholly-owned, potent, highly selective, small molecule inhibitor of CSF-1R kinase activity. Array is advancing a Phase 1/2 dose escalation immuno-oncology trial of ARRY-382 in combination with pembrolizumab (Keytruda®), a Programmed Cell Death Receptor 1 (PD-1) antibody, in patients with advanced solid tumors.

Clinical Trials

Trial Data
Trial Title
Program: ARRY-382
Phase: 2
Disease: Solid tumors
Sponsor: Array BioPharma
Trial Information: NCT02880371
Trial Title: A Study of ARRY-382 in Combination With Pembrolizumab for the Treatment of Patients With Advanced Solid Tumors

To learn more about ARRY-382 clinical trials, click here.

Publications and Presentations



Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

A phase 1b/2 dose-escalation study of ARRY-382, an oral inhibitor of colony-stimulating factor-1 receptor (CSF-1R) in combination with pembrolizumab for the treatment of patients with advanced solid tumors

Wael A. Harb, et al.



AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeutics

A Phase 1 Study of ARRY-382, an Oral Inhibitor of Colony-stimulating Factor-1 Receptor (CSF1R), in Patients with Advanced or Metastatic Cancers

J. Bendell, et al.

To view all publications, click here.

These compounds and their uses are investigational and have not been approved by the U.S. Food and Drug Administration. This information is presented only for purposes of providing a general overview of our clinical trials.